Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

MSK uncovers how interacting mutations shield breast cancer

6

Mar 2026

MSK uncovers how interacting mutations shield breast cancer

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs called CDK4/6 inhibitors. This finding, published in Nature, suggests a new strategy for predicting and preventing resistance to specific therapies based on the tumor's genetic profile.

BCAT2 enzyme identified as a target for diabetic foot recovery

6

Mar 2026

BCAT2 enzyme identified as a target for diabetic foot recovery

Diabetic macrovascular complications are the main cause of death and disability in diabetes patients, of which vascular calcification is one of the key pathological mechanisms. Calcification in atherosclerotic plaque can cause stiffness and decreased compliance of the vascular wall, and induce atherosclerotic plaque rupture, which increases the risk of acute cardiovascular events.

Study tracks surge in leucovorin after White House promotion

6

Mar 2026

Study tracks surge in leucovorin after White House promotion

A White House briefing in September 2025 that raised concerns about acetaminophen use during pregnancy and promoted the drug leucovorin as a potential autism treatment was followed by sharp changes in how doctors prescribed those medications nationwide, according to a new study.

Mussel-inspired adhesive prevents organ rejection

6

Mar 2026

Mussel-inspired adhesive prevents organ rejection

A new technology has been developed to suppress immune rejection, the biggest challenge in organ transplantation, without causing systemic side effects. A research team from Pohang University of Science and Technology (POSTECH) and Ewha Womans University has developed the "Immune-Shield" technology, which directly sprays immunosuppressants onto the surface of organs using mussel-derived adhesive protein.

A review of methionine dependency in modern cancer therapy

6

Mar 2026

A review of methionine dependency in modern cancer therapy

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.

Building global standards for antimicrobial policy

6

Mar 2026

Building global standards for antimicrobial policy

Antimicrobial resistance (AMR) threatens human, animal, and environmental health globally. An international team from leading institutions, including the University of Edinburgh, London School of Hygiene and Tropical Medicine, North Carolina State University, and the International Centre for Antimicrobial Resistance Solutions, identifies fundamental gaps in current mathematical modelling approaches that prevent translation of science into policy, including data limitations, knowledge gaps about AMU-AMR relationships, and the absence of international coordination mechanisms similar to climate change efforts. They call for transdisciplinary collaboration to build integrated modelling architectures.

Melbourne’s lab-grown "skin" revolutionizes tick research

5

Mar 2026

Melbourne’s lab-grown "skin" revolutionizes tick research

The world's first lab-based tick feeding system for bush ticks, developed by researchers at the University of Melbourne, has transformed the study of ticks and how they transmit disease. The novel, host-free technology reduces the need for animal experiments in tick studies, facilitating more ethical, reproducible research.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.